Total Payments
$93,323
2024 Payments
$6,207
Companies
15
Transactions
71
Medicare Patients
160
Medicare Billing
$76,930
Payment Breakdown by Category
Consulting$38,320 (41.1%)
Other$35,067 (37.6%)
Research$14,114 (15.1%)
Travel$4,191 (4.5%)
Food & Beverage$1,631 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $38,320 | 15 | 41.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $35,067 | 11 | 37.6% |
| Unspecified | $14,114 | 11 | 15.1% |
| Travel and Lodging | $4,191 | 16 | 4.5% |
| Food and Beverage | $1,631 | 18 | 1.7% |
Payments by Type
General
$79,209
60 transactions
Research
$14,114
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $30,060 | 1 | $0 (2017) |
| F. Hoffmann-La Roche AG | $12,904 | 18 | $0 (2021) |
| Daiichi Sankyo Inc. | $9,933 | 10 | $0 (2020) |
| Celgene Corporation | $6,507 | 3 | $0 (2018) |
| Acrotech Biopharma Inc. | $6,207 | 8 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $5,657 | 9 | $0 (2017) |
| GENZYME CORPORATION | $5,232 | 2 | $0 (2021) |
| Heron Therapeutics, Inc. | $3,831 | 4 | $0 (2018) |
| Ipsen Innovation | $3,703 | 2 | $0 (2018) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $3,146 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,207 | 8 | Acrotech Biopharma Inc. ($6,207) |
| 2021 | $12,534 | 8 | GENZYME CORPORATION ($5,232) |
| 2020 | $17,151 | 19 | Daiichi Sankyo Inc. ($9,933) |
| 2019 | $3,211 | 6 | F. Hoffmann-La Roche AG ($3,211) |
| 2018 | $13,933 | 14 | Celgene Corporation ($5,044) |
| 2017 | $40,286 | 16 | Eli Lilly and Company ($30,060) |
All Payment Transactions
71 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Acrotech Biopharma Inc. | — | Consulting Fee | Cash or cash equivalent | $749.99 | General |
| 12/09/2024 | Acrotech Biopharma Inc. | — | Consulting Fee | Cash or cash equivalent | $0.01 | General |
| 11/12/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Travel and Lodging | In-kind items and services | $28.00 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Travel and Lodging | In-kind items and services | $448.95 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Travel and Lodging | In-kind items and services | $192.66 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Food and Beverage | In-kind items and services | $162.84 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2021 | GENZYME CORPORATION | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $2,616.00 | General |
| Category: Oncology | ||||||
| 12/01/2021 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,040.00 | General |
| Category: Oncology | ||||||
| 11/03/2021 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,616.00 | General |
| 11/02/2021 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| 06/28/2021 | NOVARTIS PHARMACEUTICALS CORPORATION | TABRECTA (Drug) | Food and Beverage | In-kind items and services | $64.68 | General |
| Category: ONCOLOGY | ||||||
| 03/31/2021 | NOVARTIS PHARMACEUTICALS CORPORATION | PROMACTA (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: ONCOLOGY | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $875.89 | Research |
| Study: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH A PLATINUM AGENT CISPLATIN OR CARBOPLATIN IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1-SELECTED, CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS OR SQUAMOUS NON-SMALL CELL LUNG CANCER • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $311.35 | Research |
| Study: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH A PLATINUM AGENT CISPLATIN OR CARBOPLATIN IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1-SELECTED, CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS OR SQUAMOUS NON-SMALL CELL LUNG CANCER • Category: BioOncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $404.50 | Research |
| Study: PH III OPEN LABEL STDY ATEZO VS PLATINUM PEMETREXED GEMCITABINE FOR PDL1 CHEMO NAIVE STG IV NSCLC • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $4,219.69 | Research |
| Study: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH A PLATINUM AGENT CISPLATIN OR CARBOPLATIN IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1-SELECTED, CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS OR SQUAMOUS NON-SMALL CELL LUNG CANCER • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $364.55 | Research |
| Study: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH A PLATINUM AGENT CISPLATIN OR CARBOPLATIN IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1-SELECTED, CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS OR SQUAMOUS NON-SMALL CELL LUNG CANCER, A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH GEMCITABINE CISPLATIN OR CARBOPLATIN FOR PD-L1-SELECTED, CHEMOTHERAPY NAIVE PATIENTS WITH STAGE • Category: BioOncology | ||||||
| 06/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $807.99 | Research |
| Study: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH A PLATINUM AGENT CISPLATIN OR CARBOPLATIN IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1-SELECTED, CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS OR SQUAMOUS NON-SMALL CELL LUNG CANCER • Category: BioOncology | ||||||
| 06/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $486.24 | Research |
| Study: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH A PLATINUM AGENT CISPLATIN OR CARBOPLATIN IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1-SELECTED, CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS OR SQUAMOUS NON-SMALL CELL LUNG CANCER • Category: BioOncology | ||||||
| 06/30/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $426.05 | Research |
| Study: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH A PLATINUM AGENT CISPLATIN OR CARBOPLATIN IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1-SELECTED, CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS OR SQUAMOUS NON-SMALL CELL LUNG CANCER • Category: BioOncology | ||||||
| 03/24/2020 | Daiichi Sankyo Inc. | — | Travel and Lodging | In-kind items and services | $120.22 | General |
| 02/27/2020 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $8,125.00 | General |
| 02/18/2020 | Daiichi Sankyo Inc. | — | Travel and Lodging | In-kind items and services | $577.74 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH A PLATINUM AGENT CISPLATIN OR CARBOPLATIN IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1-SELECTED, CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS OR SQUAMOUS NON-SMALL CELL LUNG CANCER | F. Hoffmann-La Roche AG | $7,127 | 6 |
| CC-486-NSCL-001 - Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer | Celgene Corporation | $3,444 | 1 |
| CC-486-NSCL-001 | Celgene Corporation | $1,463 | 1 |
| A phase II study of MK-3475 in patients with thymic carcinoma | Merck Sharp & Dohme Corporation | $1,310 | 1 |
| PH III OPEN LABEL STDY ATEZO VS PLATINUM PEMETREXED GEMCITABINE FOR PDL1 CHEMO NAIVE STG IV NSCLC | F. Hoffmann-La Roche AG | $404.50 | 1 |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH A PLATINUM AGENT CISPLATIN OR CARBOPLATIN IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1-SELECTED, CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS OR SQUAMOUS NON-SMALL CELL LUNG CANCER, A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH GEMCITABINE CISPLATIN OR CARBOPLATIN FOR PD-L1-SELECTED, CHEMOTHERAPY NAIVE PATIENTS WITH STAGE | F. Hoffmann-La Roche AG | $364.55 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 59 | 192 | $77,895 | $24,076 |
| 2021 | 4 | 84 | 319 | $109,755 | $45,267 |
| 2020 | 1 | 17 | 74 | $33,670 | $7,587 |
Total Patients
160
Total Services
585
Medicare Billing
$76,930
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 37 | 152 | $70,585 | $18,771 | 26.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 11 | 29 | $4,640 | $4,629 | 99.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 11 | 11 | $2,670 | $676.38 | 25.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 32 | 167 | $75,985 | $22,927 | 30.2% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 20 | 113 | $18,080 | $18,137 | 100.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $10,400 | $2,804 | 27.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 16 | 23 | $5,290 | $1,399 | 26.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 17 | 74 | $33,670 | $7,587 | 22.5% |
About Giuseppe Giaccone
Giuseppe Giaccone is a Specialist healthcare provider based in Bethesda, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/24/2008. The National Provider Identifier (NPI) number assigned to this provider is 1417193376.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Giuseppe Giaccone has received a total of $93,323 in payments from pharmaceutical and medical device companies, with $6,207 received in 2024. These payments were reported across 71 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($38,320).
As a Medicare-enrolled provider, Giaccone has provided services to 160 Medicare beneficiaries, totaling 585 services with total Medicare billing of $76,930. Data is available for 3 years (2020–2022), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Special Hospital, Hematology & Oncology
- Location Bethesda, MD
- Active Since 12/24/2008
- Last Updated 01/16/2025
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1417193376
Products in Payments
- Tecentriq (Biological) $6,709
- TECENTRIQ (Biological) $6,195
- OPDIVO (Biological) $5,657
- RYZNEUTA (Drug) $5,457
- CC-486 (Drug) $4,907
- CINVANTI (Drug) $3,831
- Somatuline (Drug) $3,703
- PROMACTA (Drug) $3,000
- LIBTAYO (Biological) $2,616
- Lenvima (Drug) $2,040
- KEYTRUDA (Biological) $1,310
- TABRECTA (Drug) $64.68
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Bethesda
Dr. Christopher Cannova, M.d, M.D
Specialist — Payments: $1.3M
Specialist $1.3M
Karen Goldenthal
Specialist — Payments: $70,925
Specialist $70,925
Gregory Kumkumian, M.d, M.D
Specialist — Payments: $7,865
Specialist $7,865
Dr. Andre Gazdag, M.d, M.D
Specialist — Payments: $7,065
Specialist $7,065
Dr. Gita Bakhshi, Md, MD
Specialist — Payments: $6,249
Specialist $6,249
Dr. Edward Bieber, M.d, M.D
Specialist — Payments: $4,630
Specialist $4,630